乐观
$100.54
情景价格
$83.910
-1.762 (-2.10%)收盘时
U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 795 outpatient physical therapy clinics in 45 states. Its reportable segments include the Physical Therapy Operations segment and the Industrial Injury Prevention Services (IIP) segment. The Physical Therapy Operations segment consists of physical therapy, speech therapy and occupational therapy clinics and home-care physical and speech therapy practices that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders, sports-related injuries, and rehabilitation of injured workers. The IIP segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers.
US Physical Therapy Inc is a good buy right now due to its current price of $85.71, which is below the analyst price target range of $90 to $98, indicating potential upside. Additionally, the company has shown a revenue growth of 8.5% year-over-year in Q2 2026, reaching $214.06 million, despite a recent earnings miss. The RSI is at 61.36, suggesting that the stock is in a healthy momentum range, and the forward P/E ratio of 27.25 indicates reasonable valuation compared to growth prospects. However, a key risk is the recent earnings miss, with EPS reported at $0.25, missing expectations by $0.53, which could impact investor sentiment.
JPMorgan
$95
2026-09-11
JPMorgan
2026-09-11
目标价
$95
Barrington
$98
2026-08-10
Barrington
2026-08-10
目标价
$98
Barrington
$90
2026-05-13
Barrington
2026-05-13
目标价
$90
Citizens
$98
2026-05-08
Citizens
2026-05-08
目标价
$98
Jefferies
$102
2026-03-09
Jefferies
2026-03-09
目标价
$102
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

U.S. Physical Therapy Appoints New Board Member

U.S. Physical Therapy CEO Presents at Midwest Ideas Conference

U.S. Physical Therapy Appoints New CFO

USPH (USPH) Q2 2026 Earnings Call Transcript

U.S. Physical Therapy Reports Q2 Earnings Miss with Revenue Beat
U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 795 outpatient physical therapy clinics in 45 states. Its reportable segments include the Physical Therapy Operations segment and the Industrial Injury Prevention Services (IIP) segment. The Physical Therapy Operations segment consists of physical therapy, speech therapy and occupational therapy clinics and home-care physical and speech therapy practices that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders, sports-related injuries, and rehabilitation of injured workers. The IIP segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).
US Physical Therapy Inc is a good buy right now due to its current price of $85.71, which is below the analyst price target range of $90 to $98, indicating potential upside. Additionally, the company has shown a revenue growth of 8.5% year-over-year in Q2 2026, reaching $214.06 million, despite a recent earnings miss. The RSI is at 61.36, suggesting that the stock is in a healthy momentum range, and the forward P/E ratio of 27.25 indicates reasonable valuation compared to growth prospects. However, a key risk is the recent earnings miss, with EPS reported at $0.25, missing expectations by $0.53, which could impact investor sentiment.
7 analysts cover USPH: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 101.50.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。